E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
Musa Yilmaz,Hagop M. Kantarjian,Xuemei Wang,Joseph D. Khoury,Farhad Ravandi,Jeffrey L. Jorgensen,Nicholas J. Short,Sanam Loghavi,Jorge E. Cortes,Guillermo Garcia-Manero,Tapan M. Kadia,Koji Sasaki,Marina Konopleva,Koichi Takahashi,William G. Wierda,Nitin Jain,Srdan Verstovsek,Zeev Estrov,Prithviraj Bose,Sherry Pierce,Rebecca Garris,Susan O'Brien,Elias Jabbour +22 more
TL;DR: Earlier achievement of MRD negative remission is a stronger prognostic factor for survival than KMT2A (MLL) rearrangement and MRD positivity at 1TP, which were the only factors correlated with worse OS.
Journal ArticleDOI
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Elias Jabbour,Koji Sasaki,Nicholas J. Short,Farhad Ravandi,Xuelin Huang,Joseph D. Khoury,Rashmi Kanagal-Shamanna,Jeffrey L. Jorgensen,Issa F. Khouri,Partow Kebriaei,Nitin Jain,Yesid Alvarado,Tapan M. Kadia,Shilpa Paul,Guillermo Garcia-Manero,Bouthaina S. Dabaja,Jan A. Burger,Courtney D. DiNardo,Naval A. Daver,Guillermo Montalban-Bravo,Musa Yilmaz,Maro Ohanian,Alessandra Ferrajoli,Jovitta Jacob,Meagan Rostykus,Rebecca Garris,Susan O'Brien,Hagop M. Kantarjian +27 more
TL;DR: The sequential addition of blinatumomab might improve outcome in patients with R/R ALL and the combination of inotuzumab with low‐intensity mini–hyper‐CVD has shown encouraging results.
Journal ArticleDOI
SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
TL;DR: The major genomic and molecular prognostic factors in Ph+ ALL are reviewed and the current and future treatment paradigms for this disease are discussed.
Journal ArticleDOI
Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients
Michael Andreeff,Zhihong Zeng,Mary A. Kelly,Rui-Yu Wang,Teresa McQueen,Seshagiri Duvvuri,Gul Nowshad,Gautam Borthakur,Jan A. Burger,Tapan M. Kadia,Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian,Marina Konopleva +13 more
TL;DR: The combination of G-CSF+Plerixa for appears superior in increasing the number of circulating leukemic blasts and stem/progenitor cells in FLT3-ITD AML, as compared to Plerixafor alone in R/R AML.
Journal ArticleDOI
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
Curtis Lachowiez,Sanam Loghavi,Ken Furudate,Guillermo Montalban-Bravo,Abhishek Maiti,Tapan M. Kadia,Naval Daver,Gautam Borthakur,Naveen Pemmaraju,Koji Sasaki,Yesid Alvarado,Musa Yilmaz,Nicholas J. Short,Kelly S. Chien,Maro Ohanian,Sherry Pierce,Keyur P. Patel,Elias Jabbour,Farhad Ravandi,Hagop M. Kantarjian,Guillermo Garcia-Manero,Koichi Takahashi,Marina Konopleva,Courtney D. DiNardo +23 more
TL;DR: In this paper, the authors compared outcomes in patients with spliceosome mutations vs wild-type patients treated with hypomethylating agents in combination with venetoclax (HMA+VEN) for secondary acute myeloid leukemia cases.